Skip to main content

Medicines labeled for the same conditions

Alternatives to empagliflozin and linagliptin and metformin

21 other medicines are given the same way (oral) and in the same FDA class as empagliflozin and linagliptin and metformin or labeled mainly for the same use (type 2 diabetes); 9 are in its class, sodium-glucose cotransporter 2 inhibitors: dapagliflozin, sitagliptin, alogliptin, alogliptin and pioglitazone and 5 more; the others include 3 sulfonylureas, 2 peroxisome proliferator receptor gamma agonists and 2 glinides (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.184 per dapagliflozin 10 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).

Which medicines are labeled for the same conditions as empagliflozin and linagliptin and metformin?

Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA classShared indicationGeneric labelers (oral)Pharmacy costBoxed warningShortage
Empagliflozin and linagliptin and metforminsodium-glucose cotransporter 2 inhibitorthis medicinenone listed$11.28 per tablet 10-5-1,000 mg tabletYesNo current entry
Dapagliflozinsodium-glucose cotransporter 2 inhibitor · same classType 2 diabetes22 labelers$0.184 per tablet 10 mg tabletNoNo current entry
Sitagliptindipeptidyl peptidase 4 inhibitor · same classType 2 diabetes4 labelers$3.77 per tablet 100 mg tabletNoNo current entry
Alogliptindipeptidyl peptidase 4 inhibitor · same classType 2 diabetesnone listed$4.96 per tablet 12.5 mg tabletNoNo current entry
Alogliptin and pioglitazoneperoxisome proliferator receptor gamma agonist · same classType 2 diabetesnone listed$4.73 per tablet 25-15 mg tabletYesNo current entry
Canagliflozinsodium-glucose cotransporter 2 inhibitor · same classType 2 diabetesnone listed$19.13 per tablet 100 mg tabletNoNo current entry
Saxagliptindipeptidyl peptidase 4 inhibitor · same classType 2 diabetes3 labelers$1.04 per tablet 5 mg tabletNoNo current entry
Bexagliflozinsodium-glucose cotransporter 2 inhibitor · same classType 2 diabetesnone listedn/aNoNo current entry
Ertugliflozin and sitagliptindipeptidyl peptidase 4 inhibitor · same classType 2 diabetesnone listed$17.59 per tablet 15-100 mg tabletNoNo current entry
Dapagliflozin and saxagliptinsodium-glucose cotransporter 2 inhibitor · same classType 2 diabetes1 labelern/aNoNo current entry
GlipizidesulfonylureaType 2 diabetes31 labelers$0.0339 per tablet 5 mg tabletNoNo current entry
GlimepiridesulfonylureaType 2 diabetes29 labelers$0.0507 per tablet 4 mg tabletNoNo current entry
Pioglitazoneperoxisome proliferator receptor gamma agonistType 2 diabetes22 labelers$0.0675 per tablet 15 mg tabletYesNo current entry
GlyburidesulfonylureaType 2 diabetes16 labelers$0.0643 per tablet 5 mg tabletNoA presentation being discontinued
RepaglinideglinideType 2 diabetes7 labelers$0.0987 per tablet 1 mg tabletNoNo current entry
NateglinideglinideType 2 diabetes9 labelers$0.179 per tablet 60 mg tabletNoNo current entry
Acarbosealpha-glucosidase inhibitorType 2 diabetes6 labelers$0.274 per tablet 100 mg tabletNoNo current entry
SemaglutideGLP-1 receptor agonistType 2 diabetesnone listed$33.13 per tablet 1.5 mg tabletYesA presentation being discontinued
Miglitolalpha-glucosidase inhibitorType 2 diabetes2 labelersn/aNoNo current entry
Glimepiride and pioglitazoneperoxisome proliferator receptor gamma agonistType 2 diabetesnone listed$10.52 per unit 30-4YesNo current entry
ErtugliflozinType 2 diabetesnone listed$11.44 per tablet 15 mg tabletNoNo current entry
Insulin glargineinsulin analogType 2 diabetesnone listedn/aNoA presentation being discontinued

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What do pharmacies pay for each?

The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What next?

Empagliflozin and linagliptin and metformin: the full record
label, generics, price, shortages, recalls